Journal of Clinical Oncology
Articles in this Issue
A qualitative study of the home-based time burdens faced by persons affected by GI cancer.
822 Background: As cancer care is increasingly delivered at home, more tasks and responsibilities fall on patients and informal care partners. This is esp...
KIRROS: A phase II trial in progress of first-line atezolizumab (atezo) with or without bevacizumab (bev) in patients with unresectable hepatocellular carcinoma (HCC) and Child-Pugh B (CPB) cirrhosis.
TPS647 Background: HCC treatment is more complex for the sizable proportion of patients with CPB cirrhosis. These patients have poor survival due to both...
Association of GPR120 and NGF with perineural invasion in cholangiocarcinoma: Clinical and experimental insights.
622 Background: Cholangiocarcinoma (CCA) is a highly malignant biliary tumor characterized by frequent perineural invasion (PNI), which is associated with...
Phase Ib study of gevokizumab (GEVO) in combination with standard-of-care (SoC) anticancer therapies in patients (pts) with metastatic colorectal cancer (mCRC), metastatic gastroesophageal cancer (mGEC), and metastatic renal cell cancer (mRCC).
135 Background: GEVO, a humanized monoclonal antibody, binds to interleukin-1β (IL-1β) and inhibits its activity. We report results from a phase Ib study...
Physical activity and sedentary behavior patterns after early-onset colorectal cancer diagnosis.
74 Background: Sedentary lifestyle and physical inactivity are established risk factors for colorectal cancer diagnosed among adults younger than age 50 y...
Validation of PDACai v2.0 in predicting relative benefit from frontline FOLFIRINOX (FFX) and gemcitabine/nab-paclitaxel (GA) for patients (pts) with metastatic pancreatic cancer (mPDAC).
776 Background: Novel biomarkers beyond genomic alterations in DDR pathway genes (e.g. BRCA1/2 ) have the potential to optimize fr...
Final analysis of modified (m)-FOLFOXIRI plus cetuximab versus bevacizumab for <i>RAS</i> wild-type and left-sided metastatic colorectal cancer: The DEEPER trial (JACCRO CC-13).
17 Background: The DEEPER trial (NCT02515734), which evaluated m-FOLFOXIRI (irinotecan 150 mg/m², oxaliplatin 85 mg/m², 5-FU 2400 mg/m²) plus cetuximab (c...
Prognostic factors for gastric cancer patients with positive peritoneal cytology who underwent upfront surgery.
400 Background: Positive peritoneal cytology (CY1) is classified as Stage IV disease, the standard treatment for which is systemic chemotherapy. However,...
Trends in incidence and survival in anal adenocarcinoma: A SEER study of racial and age disparities.
1 Background: Anal adenocarcinoma, a rare but increasingly diagnosed malignancy, has demonstrated rising incidence rates, warranting a deeper analysis of...
Retrospective study of fluoropyrimidine chemotherapy dosing and toxicity in patients with screen-detected deleterious <i>DPYD</i> gene variants.
293 Background: Fluoropyrimidine chemotherapy agents are commonly used to treat solid tumors. Fluoropyrimidines are degraded by the enzyme dihydropyridine...
A systematic literature review of studies assessing first-line (1L) treatments in patients with advanced, grade 2/3 (G2/G3) gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
663 Background: There is no universally accepted standard of care for newly diagnosed patients with G2/G3 advanced GEP-NETs. The phase 3 NETTER-2 trial sh...
Patterns of radiological progression in participants (pts) with embolization-eligible hepatocellular carcinoma (HCC) treated with durvalumab (D) + bevacizumab (B) + transarterial chemoembolization (TACE) and placebos + TACE: EMERALD-1 post hoc analysis.
574 Background: EMERALD-1 (NCT03778957) met its primary endpoint, demonstrating improved progression-free survival (PFS) in pts with locoregional HCC trea...
Phase II study of neoadjuvant NALIRIFOX followed by chemoradiation with paclitaxel and carboplatin in locally advanced gastroesophageal cancer.
452 Background: We performed a single-arm phase II study of neoadjuvant NALIRIFOX and chemoradiation (CRT) with concurrent carboplatin/taxol (C/T) followe...
Assessing socioeconomic disparities and the likelihood of multimodal treatment utilization in patients with pancreatic cancer using SEER Medicare data.
677 Background: Optimal treatment for pancreatic cancer necessitates multimodal therapies combining surgery, chemotherapy, and radiation. Socioeconomic de...
Development and regulatory approval of a new systemic targeted therapy for advanced hepatocellular carcinoma.
613 Background: There are no commercially available devices for the treatment of patients with advanced hepatocellular carcinoma who have failed 1st line...
Alteration of gut microbiota in patients with advanced hepatocellular carcinoma.
641 Background: Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the third leading cause of cancer-related death worldwide. Desp...
Colorectal cancer legal and administrative burden support (COLLABS): A pilot clinical trial.
TPS307 Background: Patients with colorectal cancer often have health-related social needs (e.g. food insecurity, housing instability, employment loss). Fa...
Concordance between PD-L1 assays 28-8 and SP263 and their respective scoring algorithms in procured upper gastrointestinal adenocarcinoma samples.
479 Background: PD-L1 is being studied as a predictive immunohistochemical (IHC) biomarker for gastroesophageal junction (GEJ), gastric (GC), and esophage...
Encorafenib and cetuximab with/without binimetinib therapies for patients with <i>BRAF</i> -mutated metastatic colorectal cancer with prognostic factors: The BEETS trial (JACCRO CC-18).
164 Background: BRAF inhibitor combination therapies, triplet (encorafenib, binimetinib and cetuximab) and doublet (encorafenib and cetuximab), have been...
Neoadjuvant PD-1 blockade in mismatch repair-deficient or microsatellite instability-high, locally advanced and resectable colorectal cancer: A retrospective real-world analysis.
185 Background: Neoadjuvant PD-1 blockade therapy has shown encouraging efficacy in patients with mismatch repair- deficient (dMMR)/microsatellite instabi...
Retrospective analysis of HAIP therapy in metastatic colorectal cancer: Efficacy, safety, and prognostic factors.
126 Background: HAIP (hepatic arterial infusion pump) therapy is a promising intervention for metastatic colorectal cancer (mCRC) with liver metastases, a...
Fruquintinib combined with PD-1 inhibitors and chemotherapy in the first-line treatment of HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma (FDZL-FIX): A single-arm, open-label phase 2 study.
461 Background: For unresectable locally advanced or metastatic HER2-negative gastric cancer (GC), the combination of chemotherapy with immunotherapy, spe...
Preclinical development of the lipid nanoparticle–based mRNA vaccine with multiple natural T cell epitopes for pancreatic cancer.
752 Background: Immunotherapy has recently emerged as a promising avenue in cancer treatment; however, its effectiveness on pancreatic ductal adenocarcino...
Efficacy and safety of HER2-targeted therapies in biliary tract cancer: A systematic review and meta-analysis of early phase clinical trials.
599 Background: Biliary tract cancers (BTC) are a rare type of gastrointestinal malignancy, often presenting in advanced stages and associated with a dism...
A mixed methods evaluation of the Canopy Cancer Collective’s implementation of network-wide screening initiative in 2023.
709 Background: The Canopy Cancer Collective, a Learning Health Network (LHN) comprised of 14 pancreatic cancer centers across the U.S., set ambitious goa...